173 related articles for article (PubMed ID: 15830142)
1. Development of a prolactin receptor-targeting fusion toxin using a prolactin antagonist and a recombinant form of Pseudomonas exotoxin A.
Langenheim JF; Chen WY
Breast Cancer Res Treat; 2005 Apr; 90(3):281-93. PubMed ID: 15830142
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of oncogene STAT3 phosphorylation by a prolactin antagonist, hPRL-G129R, in T-47D human breast cancer cells.
Cataldo L; Chen NY; Yuan Q; Li W; Ramamoorthy P; Wagner TE; Sticca RP; Chen WY
Int J Oncol; 2000 Dec; 17(6):1179-85. PubMed ID: 11078803
[TBL] [Abstract][Full Text] [Related]
3. Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation.
Llovera M; Pichard C; Bernichtein S; Jeay S; Touraine P; Kelly PA; Goffin V
Oncogene; 2000 Sep; 19(41):4695-705. PubMed ID: 11032019
[TBL] [Abstract][Full Text] [Related]
4. Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer.
Beck MT; Chen NY; Franek KJ; Chen WY
Cancer Res; 2003 Jul; 63(13):3598-604. PubMed ID: 12839947
[TBL] [Abstract][Full Text] [Related]
5. A novel design of targeted endocrine and cytokine therapy for breast cancer.
Zhang G; Li W; Holle L; Chen N; Chen WY
Clin Cancer Res; 2002 Apr; 8(4):1196-205. PubMed ID: 11948133
[TBL] [Abstract][Full Text] [Related]
6. Human prolactin and its antagonist, hPRL-G129R, regulate bax and bcl-2 gene expression in human breast cancer cells and transgenic mice.
Peirce SK; Chen WY
Oncogene; 2004 Feb; 23(6):1248-55. PubMed ID: 14647416
[TBL] [Abstract][Full Text] [Related]
7. In vitro studies of a prolactin antagonist, hPRL-G129R in human breast cancer cells.
Ramamoorthy P; Sticca R; Wagner TE; Chen WY
Int J Oncol; 2001 Jan; 18(1):25-32. PubMed ID: 11115535
[TBL] [Abstract][Full Text] [Related]
8. A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis.
Chen WY; Ramamoorthy P; Chen N; Sticca R; Wagner TE
Clin Cancer Res; 1999 Nov; 5(11):3583-93. PubMed ID: 10589775
[TBL] [Abstract][Full Text] [Related]
9. A Novel Mechanism of hPRL-G129R, a Prolactin Antagonist, Inhibits Human Breast Cancer Cell Proliferation and Migration.
Li R; Yang Y; Lan H; Wang Y; Ge Z; Liu X; Zhou Y; Zhang W; Xian L; Yuan H
Endocrinology; 2023 Nov; 164(12):. PubMed ID: 37934803
[TBL] [Abstract][Full Text] [Related]
10. Regulation of bcl-2 gene expression in human breast cancer cells by prolactin and its antagonist, hPRL-G129R.
Beck MT; Peirce SK; Chen WY
Oncogene; 2002 Aug; 21(33):5047-55. PubMed ID: 12140755
[TBL] [Abstract][Full Text] [Related]
11. In vivo studies of the anti-tumor effects of a human prolactin antagonist, hPRL-G129R.
Chen NY; Holle L; Li W; Peirce SK; Beck MT; Chen WY
Int J Oncol; 2002 Apr; 20(4):813-8. PubMed ID: 11894130
[TBL] [Abstract][Full Text] [Related]
12. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells.
Scotti ML; Langenheim JF; Tomblyn S; Springs AE; Chen WY
Breast Cancer Res Treat; 2008 Sep; 111(2):241-50. PubMed ID: 17955362
[TBL] [Abstract][Full Text] [Related]
13. The role of human prolactin and its antagonist, G129R, in mammary gland development and DMBA-initiated tumorigenesis in transgenic mice.
Tomblyn S; Langenheim JF; Jacquemart IC; Holle E; Chen WY
Int J Oncol; 2005 Nov; 27(5):1381-9. PubMed ID: 16211235
[TBL] [Abstract][Full Text] [Related]
14. Prolactin receptor antagonism uncouples lipids from atherosclerosis susceptibility.
van der Sluis RJ; van den Aardweg T; Reuwer AQ; Twickler MT; Boutillon F; Van Eck M; Goffin V; Hoekstra M
J Endocrinol; 2014 Sep; 222(3):341-50. PubMed ID: 25063756
[TBL] [Abstract][Full Text] [Related]
15. Stromal-epithelial interactions modulate cross-talk between prolactin receptor and HER2/Neu in breast cancer.
Xu C; Langenheim JF; Chen WY
Breast Cancer Res Treat; 2012 Jul; 134(1):157-69. PubMed ID: 22270933
[TBL] [Abstract][Full Text] [Related]
16. Novel reagents for human prolactin research: large-scale preparation and characterization of prolactin receptor extracellular domain, non-pegylated and pegylated prolactin and prolactin receptor antagonist.
Oclon E; Solomon G; Hayouka Z; Salame TM; Goffin V; Gertler A
Protein Eng Des Sel; 2018 Jan; 31(1):7-16. PubMed ID: 29281090
[TBL] [Abstract][Full Text] [Related]
17. Prolactin receptor antagonists that inhibit the growth of breast cancer cell lines.
Fuh G; Wells JA
J Biol Chem; 1995 Jun; 270(22):13133-7. PubMed ID: 7768908
[TBL] [Abstract][Full Text] [Related]
18. Alteration of cell shape, adhesion, and lipid accumulation in human breast cancer cells (T-47D) by human prolactin and growth hormone.
Shiu RP; Paterson JA
Cancer Res; 1984 Mar; 44(3):1178-86. PubMed ID: 6692402
[TBL] [Abstract][Full Text] [Related]
19. A major prolactin-binding complex on human milk fat globule membranes contains cyclophilins A and B: the complex is not the prolactin receptor.
Lorenson MY; Ueda EK; Chen KE; Walker AM
Am J Physiol Endocrinol Metab; 2012 Mar; 302(5):E585-94. PubMed ID: 22205628
[TBL] [Abstract][Full Text] [Related]
20. Two wrongs can make a right: dimers of prolactin and growth hormone receptor antagonists behave as agonists.
Langenheim JF; Tan D; Walker AM; Chen WY
Mol Endocrinol; 2006 Mar; 20(3):661-74. PubMed ID: 16269515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
